Subtypes and Prognosis of Guillain-Barré Syndrome in Southwest China

Gang Zhang¹, Qi Li¹, Rongrong Zhang¹, Xiao Wei², Junyi Wang¹, Xinyue Qin¹*

¹ Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China,
² Department of Medical Technology, Chongqing Medical and Pharmaceutical College, Chongqing, China

* Qinxinyue@yahoo.com

Abstract

The proportion of different subtypes of Guillain-Barré syndrome (GBS) and their prognosis varied significantly among different regions. This study attempts to investigate the clinical subtypes and outcome of GBS in southwest China. Patients with GBS admitted to The First Affiliated Hospital of Chongqing Medical University from January 2006 to March 2013 were included in our study. Patients were classified into acute inflammatory demyelinating polyneuropathy (AIDP) group, acute motor axonal neuropathy (AMAN) group, Miller-Fisher syndrome (MFS) group, cranial nerve variants (CNV), Bickerstaff’s brainstem encephalitis overlaps with GBS (BBE-GBS) group and unclassifiable group based on clinical features and electrophysiological findings. Hughes function grade score (HFGS) was used to assess the prognosis at 3 and 6 months. The prognosis of AMAN group was poorer than that of AIDP group at 3 month and 6 month follow-up (P < 0.001). Outcome of MFS group and that of CNV group at 6 months were both good (Hughes ≤1). Hughes ≥3 (P<0.0001, OR = 6.650, 95%CI = 2.865 to 15.023) and dysautonomia (P = 0.043, OR = 2.820, 95%CI = 1.031 to 7.715) were associated with poor outcome at 6 month follow-up. AIDP is the most common subtype of GBS. Prognosis of AMAN group and BBE-GBS group is poorer than that of AIDP group at 3 month and 6 month follow-up. Hughes ≥3 at nadir and dysautonomia are predictors of poor prognosis at 6 month follow-up.

Introduction

Guillain–Barré syndrome (GBS) is a common neurological disorder that is characterized by symmetrical weakness of the limbs, which reaches a maximum severity within 4 weeks [1,2]. Although intravenous immunoglobulin (IVIG) and plasma exchange (PE) were proven to be effective treatment options for GBS [3–5], many patients still have poor prognosis and sequelae such as decreased mobility, severe long-term fatigue syndrome and chronic pain.[6] The reported mortality of GBS varies between 3% and 7%[7–9]. Typical GBS[10] is an acute,
predominantly motor neuropathy involving distal limb paresthesias, relatively symmetric leg weakness, and frequent hyporeflexia or areflexia. Recent study suggests that some patients with GBS had normal or hyperreflexia[11,12]. According to a recent classification, Bickerstaff’s brainstem encephalitis (BBE) can also be included into GBS variants [13]. Previous reports from western countries showed that acute inflammatory demyelinating polyneuropathy (AIDP) is the most common subtype of GBS [14,15], while reports from northern China showed that acute motor axonal neuropathy (AMAN) is the most common subtype of GBS in China [16]. The proportion of different subtypes of GBS and their prognosis varied significantly among different regions [17–21].

To date, the subtypes and outcome predictors of GBS remains unknown in southwest China. We set up this study to investigate the clinical characteristics and outcome predictors of GBS in southwest China.

Materials and Methods

Patients

Institutional review board approval and informed consent were obtained. Patients with GBS who were admitted to the First Affiliated Hospital of Chongqing Medical University between January 2006 and March 2013 were included into our study. The patients were classified into the following five categories as follows: acute inflammatory demyelinating polyneuropathy (AIDP) group, acute motor axonal neuropathy (AMAN) group, Miller-Fisher syndrome (MFS) group, cranial nerve variant (CNV), Bickerstaff's brainstem encephalitis overlaps with or without Guillain-Barre syndrome (BBE-GBS) and the unclassified group based on clinical features and electrophysiological findings. The unclassified group included pure sensory neuropathy of 3 cases, sensory and motor axon neuropathy of 3 cases, relapses of 2 cases.

Clinical and Electrophysiological examinations

Hughes functional grading scale (HFGS) was used for evaluating the severity of the disability [22] as follows: 6-death; 5-need mechanical ventilation; 4-bedbound; 3-walk with aid; 2-walk without aid; 1-run with minor deficit; 0-normal. Patients with a HFGS equal to or more than 3 points were defined as severe GBS. Patients with a HFGS less than 3 points were defined as mild GBS. Good prognosis was defined as HFGS/2 at 6 month follow-up. Poor prognosis was defined as HFGS>1.

Nerve conduction velocity (NCV) was performed using standard procedures. A value was defined as abnormal if it was outside the normal laboratory range, corrected for age. Patients were classified as AMAN or AIDP on the basis of the electrodiagnostic criteria reported by Hadden and his colleagues [17].

Statistical Analysis

Statistical analysis was performed by using SAS software (version 9.2). Classification variables analysis was performed with the use of Chi-square test or the exact probability method. Test level of α was corrected by Bonferroni correction in comparisons among multiple groups. Repeated Measures was used to compare the mean HFGS at nadir, 3 months and 6 months follow up among different subtypes. Univariate analysis was used to identify the factors associated with poor prognosis, which were further analyzed by Logistic regression analysis for predictors independently related to the poor prognosis. A p value less than 0.05 was considered statistically significant.
Results

Baseline Clinical Characteristics

A total of 170 patients who diagnosed with GBS were included into our study. The clinical characteristics of each GBS subtype were listed in Table 1. There were 110 (65%) males and 60 (35%) females. The mean age of the patients was 47 years (age range 14–82 years). History of antecedent infection or vaccination was observed in 49% of patients 1 to 4 weeks before the onset of GBS, which include 67 cases of upper respiratory infection, 11 case of diarrhea, 1 case of zoster herpes, 1 case of pneumonia, 1 case of injection of tetanus vaccine, 1 case of urinary tract infection. Severe GBS was observed in 142 patients (84%). The remaining 28 patients (16%) had mild GBS. A total of 30 patients had mechanical ventilation due to respiratory failure. Thirteen (7.6%) patients died during hospitalization. Patients with GBS received either intravenous immunoglobulin or plasma exchange as needed.

Comparisons of the HFGS among subgroups at nadir

The HFGS was significantly higher in patients with AMAN than those with AIDP (P = 0.027)); The HFGS was not significantly different between AIDP group and BBE-GBS group (P = 0.236); The HFGS was not significantly different between AMAN group and BBE-GBS group (P = 0.966). Incidence of patients needing mechanic ventilation between BBE-GBS group and AMAN group had no significant difference (P = 0.523), Incidence of mechanic ventilation was significantly higher in patients with BBE-GBS group than those with AIDP group (P = 0.003). Incidence of mechanic ventilation was significantly higher in AMAN group than AIDP group (P = 0.000). The HFGS score in different subgroups at different stages were illustrated and compared in Table 2 and Table 3.

Prognosis & Predictors

The results of univariate analysis of outcome predictors of patients with GBS were listed in Table 4. Patients with AIDP has significantly better outcome at 3 months follow up and 6

### Table 1. Clinical characteristics of each GBS subtype (n,%).

| Subtype [n (%)] | AIDP | AMAN | MFS | CNV | BBE-GBS | χ²-value | P-value |
|----------------|------|------|-----|-----|---------|----------|---------|
| Serious        | 91(94) | 36(97) | 0   | 1(13) | 7(87)   | 101.867  | 0.000   |
| MV             | 11(11) | 14(38) | 0   | 1(13) | 4(50)   | 18.12    | 0.000   |
| Precursor infection | 40(41) | 22(59) | 6(50) | 3(37) | 5(63)   | 4.457    | 0.384   |
| Male           | 61(63) | 24(65) | 10(83)| 7(88) | 7(88)   | 4.513    | 0.341   |
| ≥40y           | 61     | 27    | 7   | 7    | 7       | 4.580    | 0.333   |
| Bulbar paralysis | 27(28) | 14(38) | 3   | 6(75) | 6(75)   | 9.713    | 0.046   |
| Bilateral facial palsy | 18(19) | 8(22) | 4   | 5(63) | 7(88)   | 24.809   | 0.000   |
| Urinary retention | 14(14) | 8(22) | 0   | 1(12) | 1(12)   | 1.193    | 0.755   |
| Arrhythmia     | 7(7)   | 10(27) | 0   | 2(25) | 3(38)   | 12.834   | 0.005   |
| Sense disorder | 46(47) | 12(32) | 6(50) | 3(38) | 2(27)   | 3.854    | 0.426   |
| Pain           | 32(33) | 7(19) | 3(25) | 1(12) | 2(27)   | 3.768    | 0.438   |
| PE or IVIG     | 64(66) | 25(68) | 10(83) | 3(38) | 4(50)   | 5.389    | 0.250   |

Comparisons of clinical characteristics among subtype groups by chi-square, α was corrected using Bonferroni correction in chi-square of multiple comparisons, α' = 0.005.
months follow up than patients with AMAN (P = 0.001; P = 0.000, respectively) and patients with BBE-GBS (P = 0.000; P = 0.0001, respectively); Prognosis of AMAN group and BBE-GBS group at 3 months follow up (P = 0.070) and 6 months follow up (P = 0.161) had no significant difference. Prognosis of MFS group and that of CNV group at 6 months were both good (HFGS ≤ 1). The results of predictors of prognosis were showed in Table 5.

### Discussion

GBS includes many subtypes such as AIDP, AMAN, FS, BBE-GBS, etc. AIDP and AMAN was referred frequently in the previous reports [15,17,23]. Report from northern China suggest that AMAN accounts for approximately 65% of patients with GBS [16]. In another study, Ye Y, et al reported that AMAN accounts for 33% in northeast China [23]. Strikingly, data from European and north America suggested that AMAN constitute only 1 to 3 percent of GBS [15,17]. In our study, we reported that 22% of GBS cases are AMAN in southwest China. Consistent with reports from other parts of China, we found that the AMAN subtype is more common in China. However, AMAN only accounts for 22% of cases in southwest China, suggesting that significant geographical distribution of AMAN in China. Emerging evidences from immunological and clinical studies [24–26] suggested that patients may develop AMAN after campylobacter jejuni enteritis. Therefore we postulated that the geographical variations of campylobacter jejuni infection among different regions and countries may contribute to the strikingly different distribution of AMAN.

In our study, we found that MFS or MFS-GBS account for 7% of GBS cases. In sharp contrast, Mitsui Y et al reported 26% of GBS patients are MFS-GBS in Japan [14]. Similarly, Ng YS and colleagues demonstrated that MFS constitute 25% of GBS in Singapore [19]. We also found that both CNV and BBE-GBS is up to 5% in our study. A retrospective study of 43

### Table 2. Mean value of HFGS score in different subgroups at different stages (mean ± SD).

| HFGS score time | Mean value of each subtype |
|----------------|---------------------------|
|                | AIDP(n = 73) | AMAN(n = 35) | AMFS(n = 12) | CNV(n = 7) | BBE-GBS(n = 7) |
| nadir          | 3.71±0.88   | 4.40±1.06   | 1.67±0.71   | 2.00±0.58 | 4.57±1.40    |
| 3 months       | 1.20±1.18   | 1.54±1.45   | 1.67±0.71   | 0.57±0.53 | 2.67±1.75    |
| 6 months       | 0.62±0.88   | 1.21±1.17   | 0.72±0.79   | 0.29±0.49 | 2.00±1.67    |

doi:10.1371/journal.pone.0133520.t002

### Table 3. Comparisons of HFGS score in different subgroups at different stages.

|                | F-value | P-value |
|----------------|---------|---------|
| AIDP/AMAN      | 4.961   | 0.027   |
| AIDP/MFS       | 14.083  | 0.000   |
| AIDP/CNV       | 8.565   | 0.004   |
| AIDP/BBE-GBS   | 1.408   | 0.236   |
| AMAN/MFS       | 23.147  | 0.000   |
| AMAN/CNV       | 14.862  | 0.000   |
| AMAN/BBE-GBS   | 0.000   | 0.966   |
| MFS/CNV        | 0.000   | 0.966   |
| MFS/BBE-GBS    | 12.967  | 0.000   |
| CNV/BBE-GBS    | 9.745   | 0.002   |

doi:10.1371/journal.pone.0133520.t003
patients reported that both MFS and BBE constitute 7% of GBS patients, CNV count for 5% of GBS patients in Taiwan [27].

In our study, mild patients only account for 16% of cases. We found that 84% of patients with GBS are severe cases. These findings are consistent with reports from northeast of China, which demonstrated that up to 80% of cases were severe GBS [23]. The severe GBS constitute 67% in Europe [20] and 42% in United States [21]. Our findings demonstrated that the proportion of severe GBS is higher in China than that of Europe and United States.

The severity of patients in different GBS subtype groups are quite different. The ratio of critically-ill patients in the AMAN group is higher than that of AIDP group in northeast China [23]. Sundar and colleagues reported that patients with axon injury were prone to have respiratory failure [28]. The data present here shows that the mean HFGS of AMAN group and ratio of mechanic ventilation were significantly higher than that of AIDP group. Patients in the CNV group were almost always mild cases. Only one patient among the eight patients of the CNV group need mechanic ventilation. The patient recovered completely. The result of our research shows that patients with AMAN group and BBE-GBS are usually severe cases and are more likely to require mechanic ventilation than other subtypes of GBS.

According to a report of 132 case study from northeastern China, the prognosis of AIDP group is similar to that of AMAN group at 6 moth follow-up [23]. Another study from England suggested that axonal lesion pattern is associated with poor prognosis [28].

| Impact factors | Good prognosis | Poor prognosis | χ²-value | P-value |
|----------------|----------------|---------------|----------|---------|
| Male           | 58(63)         | 34(72.3)      | 0.201    | 0.273   |
| Age>60years    | 42(45.7)       | 29(61.7)      | 3.207    | 0.073   |
| Summer & Fall  | 42(45.7)       | 22(46.8)      | 0.017    | 0.897   |
| Precursor infection | 43(46.7)   | 25(53.2)      | 0.518    | 0.472   |
| Diarrhea       | 5(5.4)         | 5(10.6)       | 1.262    | 0.261   |
| Bulbar paralysis | 24(26.1)   | 26(55.3)      | 11.754   | 0.001   |
| Bilateral facial palsy | 17(18.5) | 17(36.2)      | 5.270    | 0.022   |
| Dysautonomia   | 22(23.9)       | 28(58.6)      | 17.177   | 0.000   |
| Peak time ≤14 days | 78(84.8) | 39(83.0)      | 0.076    | 0.803   |
| Nadir HFGS ≥3  | 70(76.1)       | 46(97.9)      | 10.692   | 0.001   |
| Pain           | 20(21.7)       | 9(19.1)       | 0.126    | 0.722   |
| Numbness       | 45(48.9)       | 20(42.6)      | 0.505    | 0.477   |
| IVIG/PE        | 60(65.2)       | 33(70.2)      | 0.351    | 0.554   |
| Axonal injury  | 16(18.0)       | 20(44.4)      | 10.262   | 0.001   |
| Diarrhea       | 5(5.4)         | 5(10.6)       | 1.262    | 0.261   |

doi:10.1371/journal.pone.0133520.t004

| Related factor | B     | S.E   | Wals  | P       | OR     | OR 95% CI |
|----------------|-------|-------|-------|---------|--------|-----------|
|                 |       |       |       |         |        | Lower limit | Upper limit |
| Dysautonomia    | 1.0367| 0.5135| 4.0755| 0.0435  | 2.820  | 1.031      | 7.715  |
| Nadir HFGS ≥3   | 1.8810| 0.4227| 19.7999| < .0001 | 6.560  | 2.865      | 15.023 |
| Constant        | -8.4265| 1.6893| 24.8830| < .0001 |        |            |        |

doi:10.1371/journal.pone.0133520.t005
were followed up in our research, prognosis of AMAN group was poorer than that of AIDP group at 3 month and 6 month follow-up.

A recent study from Japan showed that patients with MFS usually had good recovery and had no residual symptoms [29]. In another study of 65 patients from south China, the authors demonstrated that patients with MFS may have good recovery and these patients were not treated with immunomodulating therapy [30]. In the present study, twelve MFS patients were all completely recovered at 6 month follow-up. Our findings corroborates with previous reports from Japan and southern China.

Patients with cranial nerve variant of GBS usually have good prognosis. An Indian study involving 38 patients with cranial nerve palsies showed that cranial nerve palsies recovered completely at the end of 3 month after onset of symptoms[31]. Our study shows that patients with pure cranial nerve palsies had good prognosis at 6 month after onset of symptoms. All 7 patients with cranial nerve variant have complete recovery at 6 month follow-up.

GBS was once considered as a disease that only affected periphery nerve. The recent discovery of anti-GQ1b antibodies in patients with GBS, MFS and BBE provided important evidence that these disorders formed part of the same disease spectrum[32]. A recent study revealed that anti-GQ1b antibodies were present in 83% of patients with MFS and 68% of patients with BBE [27], suggesting that central nervous system can also be involved in GBS. In a study of 62 patients in Japan[33], 75% of the 37 patients with BBE-GBS have good prognosis at 6 month follow-up and 25% have residual weakness. However, only 2 of 7 patients with BBE-GBS in our study have a good prognosis. The discrepancies between the prognosis of patients with BBE-GBS in the present study and that of earlier studies suggest that substantial geographical variation of GBS prognosis. Our findings suggest that the prognosis of BBE-GBS and AMAN are worse than that of patients with AIDP.

We also found that HFGS at nadir equal or exceeded 3, dysautonomia are independent predictors of poor outcome at 6 month follow-up. A study from India also show that peak disability, dysautonomia are related to the poor recovery at 3 months [34]. A high grade on the GBS Disability Scale at neurological examination, diarrhea preceding GBS onset [35–38] and advanced age are all predictors of poor outcome[6,7,35,37].

In summary, this report is the first time provide the data on GBS subtypes and outcome in southwest China. Further studies are needed to clarify the underlying mechanism of regional variation in GBS subtypes and outcome in China.

Author Contributions
Conceived and designed the experiments: GZ XYQ. Performed the experiments: GZ QL RRZ JYW. Analyzed the data: GZ XW QL XYQ. Contributed reagents/materials/analysis tools: RRZ JYW XW QL GZ. Wrote the paper: GZ QL XYQ.

References
1. Hughes RA, Comblath DR. Guillain-Barre syndrome. Lancet. 2005; 366(9497):1653–66. doi: 10.1016/S0140-6736(05)67665-9 PMID: 16271648.
2. Yuki N, Hartung HP. Guillain-Barre syndrome. The New England journal of medicine. 2012; 366(24):2294–304. doi: 10.1056/NEJMra1114525 PMID: 22694009.
3. Hughes RA, Swan AV, Raphael JC, Anname D, van Koningsveld R, van Doorn PA. Immunotherapy for Guillain-Barre syndrome: a systematic review. Brain: a journal of neurology. 2007; 130(Pt 9):2245–57. doi: 10.1093/brain/awm004 PMID: 17337484.
4. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2014; 9:CD002063. doi: 10.1002/14651858.CD002063.pub6 PMID: 25238327.
5. Hughes RA, Pritchard J, Hadden RD. Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barre syndrome. The Cochrane database of systematic reviews. 2013; 2:CD008630. doi: 10.1002/14651858.CD008630.pub3 PMID: 23450584.

6. Witsch J, Gallidiks N, Bender A, Kollmar R, Bösel J, Hobohm C, et al. Long-term outcome in patients with Guillain-Barré syndrome requiring mechanical ventilation. Journal of neurology. 2013; 260 (5):1367–74. doi: 10.1007/s00415-012-6806-x PMID: 23299621.

7. Dhar R, Stitt L, Hahn AF. The morbidity and outcome of patients with Guillain-Barre syndrome admitted to the intensive care unit. Journal of the neurological sciences. 2008; 264(1–2):121–8. doi: 10.1016/j.jns.2007.08.005 PMID: 17881005.

8. Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008; 70(18):1608–13. doi: 10.1212/01.wnl.0000310983.38724.d4 PMID: 18443311.

9. van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barre syndrome. Neurology. 2013; 80(18):1650–4. doi: 10.1212/00005261-000000000000005 PMID: 23576619.

10. Criteria for diagnosis of Guillain-Barre syndrome. Annals of neurology. 1978; 3(6):565–6. doi: 10.1002/ana.410030628 PMID: 677829.

11. Yuki N, Hirata K. Preserved tendon reflexes in Campylobacter neuropathy. Annals of neurology. 1998; 43(4):546–7. doi: 10.1002/ana.410430424 PMID: 9546342.

12. Kuwabara S, Nakata M, Sung-JY, Mori M, Kato N, Hattori T, et al. Hyperreflexia in axonal Guillain-Barre syndrome subsequent to Campylobacter jejuni enteritis. Journal of the neurological sciences. 2002; 199(1–2):89–92. PMID: 12084449.

13. Wakerley B, Uncini A, Yuki N, Group GBSC, Group GBSC. Guillain-Barré and Miller Fisher syndromes—new diagnostic classification. Nature reviews Neurology. 2014; 10:537–44. doi: 10.1038/nrneurol.2014.138 PMID: 25072194.

14. Mitsui Y, Kusunoki S, Arimura K, Kaji R, Kanda T, Kuwabara S, et al. A multicentre prospective study of Guillain-Barre Syndrome in Japan: a focus on the incidence of subtypes. Journal of neurology, neurosurgery, and psychiatry. 2015; 86(1):110–4. doi: 10.1136/jnnp-2013-306509 PMID: 24273220.

15. Omejec G, Podnar S. Retrospective analysis of Slovenian patients with Guillain-Barre Syndrome. Journal of the peripheral nervous system: JPNS. 2012; 17(2):217–9. doi: 10.1111/j.1529-8027.2012.00397.x PMID: 22734909.

16. Ho TW, Mishu B, Li CY, Gao CY, Comblath DR, Griffin JW, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain: a journal of neurology. 1995; 118 (Pt 3):597–605. PMID: 7600081.

17. Hadden RD, Comblath DR, Hughes RA, Zielasek J, Hartung HP, Toyka KV, et al. Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Annals of neurology. 1998; 44(5):780–8. doi: 10.1002/ana.410440512 PMID: 9818934.

18. Ma YM, Liu TK, Wong V. Guillain-Barre syndrome in southern Chinese children: 32 year experience in Hong Kong. Pediatrics international: official journal of the Japan Pediatric Society. 2010; 52(1):13–9. doi: 10.1111/j.1442-200X.2009.02951.x PMID: 19702649.

19. Ng YS, Lo YL, Lim PA. Characteristics and acute rehabilitation of Guillain-Barre syndrome in Singapore. Annals of the Academy of Medicine, Singapore. 2004; 33(3):314–9. PMID: 15175771.

20. van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC. IVIG treatment and prognosis in Guillain-Barre syndrome. Journal of clinical immunology. 2010; 30 Suppl 1:S74–8. doi: 10.1007/s10875-010-9407-4 PMID: 20396937.

21. Vucic S, Cairns KD, Black KR, Chong PS, Cros D. Neuropathologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2004; 115(10):2329–35. doi: 10.1016/j.clinph.2004.05.009 PMID: 15351375.

22. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet. 1978; 2(8093):750–3. PMID: 80682.

23. Ye Y, Wang K, Deng F, Xing Y. Electrophysiological subtypes and prognosis of Guillain-Barre syndrome in northeastern China. Muscle & nerve. 2013; 47(1):68–71. doi: 10.1002/mus.23477 PMID: 23042578.

24. Kokubun N, Shahrizaila N, Koga M, Hirata K, Yuki N. The demyelination neuropathological criteria can be misleading in Campylobacter jejuni-related Guillain-Barré syndrome. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2013; 124(8):1671–9. doi: 10.1016/j.clinph.2013.02.010.
25. Drenthen J, Yuki N, Meulstee J, Maathuis E, van Doorn P, Visser G, et al. Guillain-Barré syndrome subtypes related to Campylobacter infection. Journal of neurology, neurosurgery, and psychiatry. 2011; 82(3):300–5. doi: 10.1136/jnnp.2010.226639 PMID: 21270063

26. Yuki N, Yamada M, Koga M, Odaka M, Susuki K, Tagawa Y, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Annals of neurology. 2001; 49(6):712–20. PMID: 11409422.

27. Lin JJ, Hsia SH, Wang HS, Lyu RK, Chou ML, Hung PC, et al. Clinical variants of Guillain-Barré syndrome in children. Pediatric neurology. 2012; 47(2):91–6. doi: 10.1016/j.pediatrneurol.2012.05.011 PMID: 22759683.

28. Gonzalez-Suarez I, Sanz-Gallego I, Rodriguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: natural history and prognostic factors: a retrospective review of 106 cases. BMC neurology. 2013; 13:95. doi: 10.1186/1471-2377-13-95 PMID: 23876199; PubMed Central PMCID: PMC3723666.

29. Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology. 2001; 56(8):1104–6. PMID: 11320188.

30. Bai H, Wang Z-L, Tan L-M, Xiao B, Goldstein J, Yang L. The effectiveness of immunomodulating treatment on Miller Fisher syndrome: a retrospective analysis of 65 Chinese patients. Journal of the peripheral nervous system: JPNS. 2013; 18(2):195–6. doi: 10.1111/jns5.12030 PMID: 23781970

31. Bhargava A, Banakar BF, Pujar GS, Khichar S. A study of Guillain-Barre syndrome with reference to cranial neuropathy and its prognostic implication. Journal of neurosciences in rural practice. 2014; 5(Suppl 1):S43–7. doi: 10.4103/0976-3147.145200 PMID: 25540538; PubMed Central PMCID: PMC4271381.

32. Shahrizaila N, Yuki N. Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. Journal of neurology, neurosurgery, and psychiatry. 2013; 84(5):576–83. doi: 10.1136/jnnp-2012-302824 PMID: 22984203.

33. Odaka M, Yuki N, Yamada M, Koga M, Takemi T, Hirata K, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barre syndrome. Brain: a journal of neurology. 2003; 126(Pt 10):2279–90. doi: 10.1093/brain/awg233 PMID: 12847079.

34. Kalita J, Misra UK, Goyal G, Das M. Guillain-Barre syndrome: subtypes and predictors of outcome from India. Journal of the peripheral nervous system: JPNS. 2014; 19(1):36–43. doi: 10.1111/jns5.12050 PMID: 24456386.

35. Hadden RD, Karch H, Hartung HP, Zielasek J, Weissbrich B, Schubert J, et al. Preceding infections, immune factors, and outcome in Guillain-Barre syndrome. Neurology. 2001; 56(6):758–65. PMID: 11274311.

36. The prognosis and main prognostic indicators of Guillain-Barre syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barre Study Group. Brain: a journal of neurology. 1996; 119(Pt 6):2053–61. PMID: 9010009.

37. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC. A clinical prognostic scoring system for Guillain-Barre syndrome. The Lancet Neurology. 2007; 6(7):589–94. doi: 10.1016/S1474-4422(07)70130-8 PMID: 17537676.

38. Visser LH, Schmitz PI, Meulstee J, van Doorn PA, van der Meche FG. Prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain-Barre Study Group. Neurology. 1999; 53(3):598–604. PMID: 10449126